NCT02978690 - Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2016

Primary Completion Date

September 20, 2017

Study Completion Date

January 10, 2018

Conditions

Psoriasis

Interventions

DRUG

Spesolimab

Solution for infusion

Trial Locations (6)

Hedi Chaker Hospital, Department of Dermatology, Tunisia

National Taiwan University Hospital, Taipei

Pusan National Univ. Hosp, Busan

HOP Saint-Louis, Paris

Hospital Sultanah Aminah, Johor Bahru

Nagoya City University Hospital, Aichi, Nagoya